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Background
The duration of antibiotic therapy in critically ill patients with
sepsis can result in antibiotic overuse, increasing the risk of
developing bacterial resistance. Procalcitonin (PCT)-guided
antibiotic use reduces antibiotic exposure in community-
acquired pneumonia. Whether it might also reduce antibiotic
exposure in severe sepsis is unknown.
Methods
Objective
To test the hypothesis that an algorithm based on serial meas-
urements of PCT allows reduction in the duration of antibiotic
therapy compared with empirical rules, and does not result in
more adverse outcomes in patients with severe sepsis and
septic shock.
Design
Single-center, non-blinded randomized controlled trial.
Setting
Mixed medical and surgical ICU at a university teaching hospi-
tal.
Subjects
79 adult patients with suspected severe sepsis or septic
shock.
Intervention
All patients had circulating PCT levels drawn daily. In patients
randomly assigned to the intervention group, antibiotics were
stopped when PCT levels had decreased 90% or more from
the initial value (if clinicians agreed) but not before Day 3 (if
baseline PCT levels were <1 mg/L) or Day 5 (if baseline PCT
levels were >1 mg/L). In control patients, clinicians decided on
the duration of antibiotic therapy based on empirical rules.
Outcome
Systemic antibiotic exposure, measured using three variables:
1) duration of antibiotic treatment, 2) antibiotic exposure days
per 1000 inpatient days, and 3) days alive without antibiotics
within the 28-day follow-up period.
Results
Patients assigned to the PCT group had 3.5-day shorter
median duration of antibiotic therapy for the first episode of
infection than control subjects (intention-to-treat, n = 79, P =
0.15). In patients in whom a decision could be taken based on
serial PCT measurements, PCT guidance resulted in a 4-day
reduction in the duration of antibiotic therapy (per protocol, n
= 68, P = 0.003) and a smaller overall antibiotic exposure (P
= 0.0002). A similar mortality and recurrence of the primary
infection were observed in PCT and control groups. A 2-day
shorter intensive care unit stay was also observed in patients
assigned to the PCT group (P = 0.03).
Conclusion
Our results suggest that a protocol based on serial PCT meas-
urement allows reducing antibiotic treatment duration and
exposure in patients with severe sepsis and septic shock with-
out apparent harm.
Commentary
Procalcitonin (PCT), the biologically active precursor of the
calcium-modulating hormone calcitonin [2], has been shown
in diverse studies to be closely associated with the humanCritical Care    Vol 12 No 6    Simon et al.
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host response to bacterial infection [3-6]. It is elaborated by
parenchymal cells throughout the body in response to endo-
toxin and several pro-inflammatory mediators (in particular
TNF-α) and its concentration appears to be roughly linear with
the degree of insult [7]. The use of circulating PCT measure-
ment to guide antibiotic therapy reduces antibiotic exposure in
patients with suspected lower respiratory tract infection in
both the inpatient and outpatient setting [8-10]. The role of
PCT in patients with more severe infections such as severe
sepsis has yet to be fully elucidated, but it has tantalizing per-
formance characteristics as a biomarker for bacterial infection,
showing diagnostic superiority to white cell count, C-reactive
protein, and a host of physiologic variables in most reports
[11]. However, these investigations suffer from the absence of
a diagnostic gold-standard, a common problem in studies of
infection [12]. The use of PCT to diagnose bacteremia or sep-
sis has been the subject of significant debate and at least
three meta-analyses, two supporting [13,14] and one discour-
aging [15] its clinical utility.
In the present single-center randomized controlled trial the
authors evaluated a protocol for antibiotic cessation based
almost entirely on plasma PCT level, with the primary outcome
relating to the duration of antibiotic exposure. Seventy-nine
intensive care unit (ICU) patients with suspected severe sep-
sis or septic shock according to ACCP-SCCM consensus cri-
teria [16] were randomized to either usual care or a protocol
arm in which the duration of antibiotics was determined by
serial PCT measurements. These patients were quite ill, with
~50% requiring vasopressors and ~80% invasive ventilation.
Serum PCT measurements were obtained daily and antibiotic
cessation was encouraged on either day 3 or day 5 (depend-
ing on the initial PCT level) in intervention patients who expe-
rienced a predefined relative or absolute decline in PCT, with
the implicit assumption that these patients had resolved their
septic focus. The intention-to-treat analysis showed a nonsig-
nificant trend toward reduced duration of antibiotics use. In the
per-protocol analysis, PCT-guided therapy not only resulted in
significant decreases in duration of antibiotic use, but a 2-day
shorter ICU stay. Mortality and infection recurrence rates were
similar between groups.
This study does have significant appeal. Rather than focusing
on whether PCT can accurately diagnose infection, the
authors have instead shown that it can be used as part of a
treatment protocol to reduce antibiotic duration in some of the
sickest ICU patients. The study does, however, have limita-
tions that deserve consideration. Important exclusion criteria
included the presence of certain difficult to eradicate patho-
gens (notably, Pseudomonas aeruginosa and Acinetobacter
baumanni), infections requiring prolonged antibiotic therapy
(e.g., endocarditis, deep abscesses) and immunosuppressed
subjects, such as those with human immunodeficiency virus,
neutropenia, or solid organ transplantation. The ultrasensitive
PCT assay used in the study is not yet widely available. Even
the standard PCT assay has a turn-around time measured in
days, rather than hours, in many academic medical centers,
such as our own where PCT is a "send out" lab. The results of
the study were only significant in the per-protocol analysis,
which was limited to patients with several days of follow-up
and without post-randomization death or diagnosis of compli-
cated infection requiring extended antibiotic therapy. This was
designed to limit the analysis to subjects in whom a decision
to stop antibiotics could actually be taken based on PCT lev-
els. Though this approach is not inherently wrong, the use of
serial PCT levels to guide therapy requires levels to be drawn
on all patients, not just those in which PCT later proves to be
of benefit, which raises issues of cost-effectiveness. Even so,
the positive trend seen in the intention-to-treat analysis is reas-
suring and may have become significant had more subjects
been enrolled.
Unfortunately, the main shortcoming of the study is that it was
not powered to answer the real question. That is, can antibiotic
exposure be safely reduced? Mortality and infection recur-
rence rates were similar between groups, suggesting that anti-
biotic use was reduced without harming patients. Yet, as the
authors point out, a study powered for these endpoints would
require several hundred patients per arm.
There are several large ongoing or recently completed multi-
center trials of PCT-guided antibiotic therapy in ICU patients
with infection. The PROcalcitonin to Reduce Antibiotic Treat-
ments in Acute-Ill Patients (PRORATA) study, a 630 patient
study in adult ICU patients with presumed bacterial infection,
completed enrollment May 2008 [17]. The Procalcitonin and
Survival Study (PASS), a 1000 patient study in adult ICU
patients with severe sepsis, is expected to complete enroll-
ment in early 2009 [18]. An additional study in 200 adult ICU
patients with suspected infection, but no clear-cut source by
clinical or microbiological criteria, is expected to close in late
2009 [19]. [1]
Recommendation
The PCT-based protocol in the study does appear to reduce
antibiotic exposure in patients with severe sepsis, but issues
of assay availability, generalizeability, safety, and cost-effec-
tiveness must be addressed before we can recommend its
routine use.
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